Arvin Cyrus Arman - 13 Feb 2023 Form 4 Insider Report for CytoDyn Inc. (CYDY)

Reporting relationship: President
Issuer ticker: CYDY
Reported as of: 13 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Feb 2023, 19:09:49 UTC
Prior SEC filing: 22 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Antonio Migliarese, Attorney-In-Fact

Key filing fact

Arvin Cyrus Arman filed Form 4 for CytoDyn Inc. (CYDY) on 14 Feb 2023.

Key facts

This page summarizes Arvin Cyrus Arman's Form 4 filing for CytoDyn Inc. (CYDY).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Feb 2023, 19:09.

Change

Previous filing in this sequence was filed on 22 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYDY transaction

Common Stock

Award

Transaction value
Shares: +434,782
Change %: +67%
Price
Shares after: 1,081,334
Date: 13 Feb 2023
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYDY transaction Derivative

Warrants (right to buy)

Award

Transaction value
Shares: +434,782
Change %
Price
Shares after: 434,782
Date: 13 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 434,782
Exercise price: $0.5000
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reported securities are included within Units purchased by the reporting person in a private placement directly with the Company. The terms are identical to a concurrent offering being conducted through a placement agent (the "Offering"). Each "Unit" consists of one share of common stock and one warrant to purchase one share of common stock.

Footnote F2

The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price.

Footnote F3

The warrants will become exercisable in full on the final closing date of the Offering. The warrants will expire five years after the exercise date.